Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

20.100
-0.300-1.47%
Volume:6.29M
Turnover:127.98M
Market Cap:22.87B
PE:-16.00
High:20.840
Open:20.400
Low:20.020
Close:20.400
52wk High:27.280
52wk Low:12.310
Shares:1.14B
HK Float Shares:1.14B
Volume Ratio:0.61
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.256
ROE:-26.91%
ROA:-14.75%
PB:4.81
PE(LYR):-16.00
PS:6.49

Loading ...

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Yesterday

Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%

MT Newswires Live
·
Yesterday

Zai Lab’s H1 2026: Revenue Slips 6%, Net Loss Deepens 14% as Licensing Spend Rises

Bulletin Express
·
Yesterday

Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires Live
·
Aug 25

Zai Lab CFO Chen Yajing Sells 260 ADS Worth $7,020

Reuters
·
Aug 22

Zai Lab: RTW Investments, LP Acquires US ADR Shares

HK Disclosure
·
Aug 21

Zai Lab Ltd.: RTW Fund Group GP, LLC Acquires Shares

HK Disclosure
·
Aug 21

ZAI LAB: Roderick Wong Acquires US ADR Shares

HK Disclosure
·
Aug 21

Historic Breakthrough in mRNA Cancer Vaccines: E Fund Biotech ETF (03186) Taps Innovation Opportunities Across Hong Kong and US Markets

Stock News
·
Aug 20

Movement Alert|ZAI LAB Rises 5.02% in Regular Trading, Efgartigimod Phase 3 Trial in Autoimmune Myositis Achieves Positive Results

Market Focus
·
Aug 20

US Treasury Turmoil Batters Tech Stocks While Banks Steady Hong Kong Market

Stock News
·
Aug 19

HK Stock Alert | Zai Lab Surges Nearly 7% in Morning Trade as argenx's FcRn-Targeted Drug Succeeds in Phase 3 Trial; Zai Holds Greater China Rights

Stock News
·
Aug 19

Movement Alert|ZAI LAB Rises 6.27% in Regular Trading, Efgartigimod Phase 3 Clinical Success Plus Broker Initiates Overweight Rating

Market Focus
·
Aug 19

Zai Lab Ltd: Efgartigimod Continues to be Evaluated as a Potential Treatment in Other Autoimmune Rheumatologic Diseases

THOMSON REUTERS
·
Aug 17

Zai Lab - Phase 3 Study Meets Primary Endpoint of Mean Total Improvement Score at Week 52

THOMSON REUTERS
·
Aug 17

Zai Lab and Argenx Announce Positive Topline Results from Phase 3 Alkivia Trial of Efgartigimod in Autoimmune Myositis

THOMSON REUTERS
·
Aug 17

Zai Lab - Efgartigimod Well-Tolerated with Consistent Safety Profile in Alkivia Study

THOMSON REUTERS
·
Aug 17

Zai Lab Ltd: Patient Improvements Observed Early and Sustained Throughout Study; Consistent Treatment Effect Across Imnm and Dm

THOMSON REUTERS
·
Aug 17

Movement Alert|ZAI LAB Declines 5.29% in Regular Trading, Profit-Taking Emerges After 30%-Plus Post-Earnings Rally

Market Focus
·
Aug 14

Zai Lab CFO Chen Yajing Sells 619 ADS Worth $15,475

Reuters
·
Aug 14